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Background: Metformin use has been associated with a reduced risk of developing cancer and an improvement in
overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant
therapy in individual cancer types has not been presented.
Patients and methods: We systematically searched research databases, conference abstracts and trial registries for
any studies reporting cancer outcomes for individual tumour types in metformin users compared with non-users, and
extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis
was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and
cancer-specific survival (CSS), to inform future trial design.
Results: Of 7670 articles screened, 27 eligible studies were identified comprising 24 178 participants, all enrolled in
observational studies. In those with early-stage colorectal cancer, metformin use was associated with a significant benefit in all
outcomes [RFS hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.47–0.85; OS HR 0.69, CI 0.58–0.83; CSS HR 0.58, CI
0.39–0.86]. For men with early-stage prostate cancer, metformin was associated with significant, or borderline significant,
benefits in all outcomes (RFS HR 0.83, CI 0.69–1.00; OS HR 0.82, CI 0.73–0.93; CSS HR 0.58, CI 0.37–0.93); however,
there was significant heterogeneity between studies. The data suggest that prostate cancer patients treated with radical
radiotherapy may benefit more from metformin (RFS HR 0.45, CI 0.29–0.70). In breast and urothelial cancer, no significant
benefits were identified. Sufficient data were not available to conduct analyses on the impact of metformin dose and duration.
Conclusions: Our findings suggest that metformin could be a useful adjuvant agent, with the greatest benefits seen in
colorectal and prostate cancer, particularly in those receiving radical radiotherapy, and randomised, controlled trials
which investigate dose and duration, alongside efficacy, are advocated.
Key words: metformin, repurposing, adjuvant, prostate cancer, colorectal cancer, breast cancer
introduction
Although cancer survival rates in the UK have doubled in the last
40 years, half of those diagnosed with cancer still die from their
disease within 10 years [1, 2]. Adjuvant treatment after poten-
tially curative cancer therapy improves survival rates, but relapse
rates remain high in some tumour types, and for others, there are
no proven adjuvant treatments. In the quest to improve cancer
outcomes, a number of established medications with known
anti-cancer properties have been considered as adjuvant anti-
cancer therapies. Examples include aspirin [3], vitamin D [4],
bisphosphonates [5], statins [6] and metformin.
Metformin exhibits a number of attributes that make it appeal-
ing for repurposing as an anti-cancer therapy. It has been in use
for over half a century and is themost widely prescribed anti-dia-
betic medication in the world [7]. Consequently, it has been
administered alongside most cancer treatments without the
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emergence of any important interactions. Additionally, data on
the toxicity profile of metformin in those without type II diabetes
mellitus (DM) are already available from clinical trials investigat-
ing its role as a treatment for polycystic ovarian syndrome [8].
Metformin is also generically available worldwide at low cost.
Metformin has been shown to have anti-cancer activity both
in vivo and in vitro [9], with the underlying mechanism subject
to ongoing investigation. It has been proposed that the anti-can-
cer properties of metformin result from both direct effects on
cancer cells, particularly through inhibition of the AMPK/
mTOR pathway [10], and indirect effects on the host, by virtue
of its blood glucose-lowering properties and anti-inflammatory
effects [11, 12]. Both mechanisms are anticipated to be impor-
tant, although their relative contribution may differ according to
cancer stage. In vivo evidence has emerged from window studies
showing an anti-proliferative effect in breast cancer [13, 14] and
a reduction in precancerous changes in the colorectum [15].
Meta-analyses have examined the role of metformin in the pri-
mary prevention of cancer, where it was found to significantly
reduce overall cancer incidence; however, findings were incon-
sistent when individual tumour types were considered [16–20].
Meta-analyses have also investigated the effect of metformin use
across all stages of disease and have found that it reduces overall
cancer mortality rates, but, again findings are conflicting for
individual tumour types [21–28], suggesting analyses are best
conduced for individual tumour types separately. Most recently,
a randomised phase III trial of non-DM patients showed that
low-dose metformin was effective in the chemoprevention of
metachronous colorectal adenomas or polyps when compared
with placebo [29].
Benefits in the primary prevention, or advanced setting, do
not necessarily translate to utility in the adjuvant setting as the
mechanism of action may be different. Our objective was to con-
duct a systematic review and meta-analysis of randomised and
non-randomised studies to investigate the effect of metformin
use compared with non-use on recurrence-free survival (RFS),
overall survival (OS) and cancer-specific survival (CSS) in adults
who have potentially curable solid tumours. There have been a
number of calls for systematic reviews and meta-analyses to be
conducted as part of the scientific justification, and to inform the
design, of new clinical trials [30, 31]. This is particularly relevant
in the field of drug repurposing. The aim of this analysis was to
advise further clinical investigation of metformin in the adjuvant
setting.
methods
All methods for this systematic review andmeta-analysis are out-
lined in a prospectively registered protocol available online [32]
(PROSPERO identifier CRD42015020519), and reporting fol-
lows PRISMA (Preferred Reporting Items for Systematic
Reviews andMeta-Analyses) guidelines.
eligibility criteria
Eligible studies include randomised, controlled trials and non-
randomised studies (observational, cohort and case–control)
that have investigated the use of metformin, with a comparator
of no metformin, in participants over 16 years old with
potentially curable solid tumours (defined as those either under-
going radical therapy with curative intent or those with an early-
stage cancer where cure is normally the objective of standard
treatment). Studies must have reported data on at least one of
RFS, CSS or OS for individual tumour types.
search strategy
Electronic searches of databases (Medline, EMBASE, Cochrane
Central Register of Controlled Trials), clinical trial registries
(clinicaltrials.gov, ISRCTN and EU Clinical Trials Register) and
conference proceedings (American Society of Clinical Oncology,
and European Society of Medical Oncology) were conducted. All
sources were searched from inception until 31May 2015 (confer-
ence abstracts 2005–2015). Bibliographies of the reports of all
identified studies and review articles were hand-searched for fur-
ther potentially eligible studies. Further details of the search
strategy are available in supplementary data S1, available at
Annals of Oncology online.
study selection
All retrieved studies were assessed for eligibility and, when suffi-
cient information was not available from the title and/or abstract,
the full-text publication or (for conference abstracts) the associ-
ated poster or presentation was acquired and where this was not
available, we contacted the study author. For studies with multi-
ple publications, or where there was overlap in the patients
studied, the most recent publication was chosen. Any queries
were checked by a second reviewer and resolved by consensus.
No study was excluded for weakness of study design or quality.
For the purpose of this analysis, studies presenting data sepa-
rately by tumour type were treated as separate studies. Articles
were grouped by cancer type according to the site of origin and
histology.
data items and collection
Data on patient characteristics, interventions and outcomes were
extracted for all studies into a predesigned table. These were
cross-checked by a second independent reviewer and any dis-
agreements were resolved by consensus. A list of data extracted is
available in supplementary data S2, available at Annals of
Oncology online. Studies were evaluated to determine whether
they accounted for potential confounding factors [body mass
index (BMI), age, gender, cancer-specific prognostic factors and
the use of other anti-DM medications], either by demonstrating
that there was no significant difference in their distribution
between treatment groups or by inclusion inmultivariable analy-
ses. In order to minimise the potential for confounding by DM
status, where the comparator included both non-DM patients
and DM non-metformin users, we extracted data based on a DM
non-metformin comparator in preference.Where a time-varying
covariate was used to model treatment effect, the most conserva-
tive HR was selected. Where reported, the HR after adjustment
for potential confounding factors was extracted in preference to
an unadjusted value. Since all eligible studies were of cohort
design, the Newcastle–Ottawa quality assessment scale for
cohort studies (NOS) [33] was used to evaluate methodological
quality.
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statistical analysis
HRs and associated statistics were either extracted directly from
the study reports or estimated from the Kaplan–Meier curves or
summary statistics using publishedmethods [34–36].Where suffi-
cient data were available on outcomes for individual cancer types,
a meta-analysis was conducted with a primary outcome of RFS
and secondary outcomes of OS and CSS. HRs were combined
across trials using a fixed-effectmodel. Heterogeneity was assessed
using the v2 test and the I2 statistic. A random-effects model
(DerSimonian and Laird) [37] was used to assess whether the
results were robust to the choice of model. Probability values were
two-sided, with P< 0.05 considered of statistical significance.
We also preplanned analyses to explore whether the size or the
direction of the effect of metformin therapy varied according to
specific study or patient characteristics, including: DM status of
the comparator group (with and without non-DM patients in
the comparator group), prostate cancer primary treatment type
(prostatectomy or radical radiotherapy) and study design. The
resulting HR estimates from study group analyses were com-
pared using the v2 test for interaction. We also planned to
explore the impact of metformin dose/exposure on the outcomes
described above where available. We also conducted unplanned
sensitivity analyses for the primary outcome of RFS where at
least two studies were available after restrictions. This was car-
ried out according to study quality (restricted to studies with an
NOS score  the median); publication type (restricted to studies
where a full publication was available); setting (restricted to hos-
pital-based studies); follow-up (restriction of follow-up <3
years); and by the potential confounding factors accounted for
(restricted to studies that adjusted for BMI, age, gender, cancer-
specific prognostic factors and other DMmedications). An addi-
tional unplanned exploratory analysis was also conducted
according to whether the study was from a Western (North
America or Europe) or non-Western population after a wide
geographical distribution of studies was noted. Study group and
sensitivity analyses were only conducted where study numbers
were sufficient to be meaningful. Statistical analyses were carried
out using STATA version 14.
results
After screening 7670 reports and conference abstracts, we identi-
fied 23 full publications and 4 conference abstracts that met our
eligibility criteria, comprising 24 178 participants [38–64]. All
were retrospective cohort studies except for one prospective
cohort study embedded in a clinical trial [41]. The PRISMA study
selection diagram is shown in Figure 1. The majority of identified
studies examined the effect of metformin in one of four tumour
types: prostate, colorectal, breast and urothelial cancer, which,
therefore, represent the main focus of this analysis. A summary of
the main characteristics for studies of breast, colorectal and pros-
tate cancer is presented in Table 1, and a table of study characteris-
tics for other cancer types is presented in Table 2.
colorectal cancer
RFS was assessed in two studies (623 patients), OS in five studies
(1936 patients) and CSS in two studies (535 patients). Overall, met-
formin use appeared to demonstrate significant improvements in
Records identified
through database
searching
(N = 7667)
Records after duplicates removed
(N = 6326)
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(N = 6326)
Full text and
abstracts/posters
assessed for eligibility
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Records excluded
(N = 6210)
Additional records
identified through
bibliographic searches
(N = 3)
Articles excluded
(total N = 80)
Includes advanced stage (N = 36)
Patient overlap with other study (N = 10)
Inadequate methods (N = 25)
Other endpoint or comparison (N = 9)
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Figure 1. PRISMA study selection diagram.
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RFS (HR 0.63, CI 0.47–0.85), OS (HR 0.69, CI 0.58–0.83) and CSS
(HR 0.58, CI 0.39–0.86) (Figure 2), although there was variation
between the results of the individual studies for RFS (I2 ¼ 83.1%,
P¼ 0.015) andOS (I2¼ 82.3 P< 0.001).When the random-effects
model was applied, the benefits seen for bothOS (HR 0.62, CI 0.40–
0.97) and CSS (HR 0.58, CI 0.39–0.86) remained, but there was no
longer a significant benefit of metformin on RFS (HR 0.62, CI 0.30–
1.29). In an unplanned exploratory analysis that grouped studies
with Western and non-Western populations separately, we found
there was a significant interaction between the effect of metformin
on OS and the population studied (v2¼ 14.31, P< 0.001). In stud-
ies in non-Western populations, there was a highly significant bene-
fit of metformin onOS (HR 0.36, CI 0.25–0.53); however, there was
evidence of heterogeneity (I2 ¼ 85.8%, P ¼ 0.013). In studies with
Western populations, only a trend towards a significant effect was
identified (OSHR 0.84, CI 0.68–1.03) with no clear evidence of het-
erogeneity (I2¼ 4.6%,P¼ 0.350). In unplanned sensitivity analyses,
there appeared to be a larger relative benefit of metformin on OS
when analyses were restricted to studies that had follow-up of >3
years (HR 0.64, CI 0.52–0.78). Further details of study group
and sensitivity analyses for all tumour types are available in
supplementary Table S1, available atAnnals of Oncology online.
prostate cancer
RFS was assessed in six studies (9330 patients), OS in four studies
(4457 patients) and CSS in three studies (1643 patients).
Metformin use demonstrated a borderline significant improve-
ment in RFS (HR 0.83, CI 0.69–1.00), and significant improve-
ments in OS (HR 0.82, CI 0.73–0.93) and CSS (HR 0.58, CI 0.37–
0.93) (Figure 3); however, the relationship was inconsistent
across studies (RFS I2 ¼ 64.8%, P ¼ 0.014; OS I2 ¼ 87.3%, P <
0.001; CSS I2¼ 75.3%, P¼ 0.017), which was reflected when the
random-effects model was applied (RFS HR 0.80, CI 0.57–1.13;
OS 0.69, CI 0.44–1.10; CSS 0.64, CI 0.19–2.12).
In a pre-specified analysis, there was significant interaction
between the effect of metformin and the primary treatment type
on RFS (v2 test for interaction 9.03, P ¼ 0.003). For patients
receiving radical radiotherapy [46, 48], there was a significant
benefit frommetformin (HR 0.45, CI 0.29–0.70), whereas no sig-
nificant benefit was seen for patients who underwent radical
prostatectomy (HR 0.94, CI 0.77–1.15) (Figure 4). Only a single
study was able to provide data on OS and CSS in those having
radical radiotherapy; however, significant improvements were
seen in both (OS 0.44, CI 0.27–0.72; CSS 0.19, CI 0.06–0.63) [46].
We found no evidence of an interaction between the effect of
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Figure 2. Colorectal cancer outcomes according to metformin use.
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metformin on RFS and the presence or absence of non-DM
patients in the comparator group (v2 0.49, P¼ 0.48).
In unplanned sensitivity analyses, there appeared to be a larger
relative benefit of metformin on RFS when analyses were
restricted to studies that had a follow-up of >3 years (HR 0.77,
CI 0.62–0.96) or considered other DMmedications in their anal-
ysis (HR 0.79, CI 0.64–0.98).
breast cancer
RFS was assessed in 2 studies containing 271 patients and OS in
3 studies including 2045 patients. Metformin demonstrated a
trend towards improvement in RFS (HR 0.77, CI 0.49–1.22)
(Figure 5); however, no effect was seen in OS (HR 0.99, CI 0.92–
1.05). There was no evidence of variation between the results of
the studies either for RFS (I2¼ 0.0%, P¼ 0.74) or OS (I2¼ 0.0%,
P ¼ 0.75). As CSS was only available for one study containing
1774 patients, no meta-analysis was possible for this outcome;
however in this study, metformin did not appear to have an
impact on CSS (HR 1.01, CI 0.86–1.19). There were insufficient
study numbers for any meaningful study group or sensitivity
analyses.
urothelial cancer
Studies included patients with upper tract urothelial carcinoma
and urothelial carcinoma of the bladder. RFS was assessed in 3
studies including 4747 patients, and OS in 3 studies including
4747 patients, of which 2 also assessed CSS including 3712
patients. There was no clear evidence that metformin improved
either RFS (HR 0.91, CI 0.73–1.14), OS (HR 0.94, CI 0.76–1.16)
or CSS (HR 0.88, CI 0.66–1.17) (Figure 6). Although there was
some evidence of inconsistency between the results of studies for
both RFS (I2¼ 59.0%, P¼ 0.087) and OS (I2–51.5%, P¼ 0.127),
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Figure 3. Prostate cancer outcomes according to metformin use.
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the results did not change significantly when the random-effects
model was applied (RFS HR 0.84, CI 0.57–1.24; OS HR 1.00, CI
0.72–1.39; CSS HR 0.88, CI 0.66–1.17). There were insufficient
study numbers for any meaningful study group or sensitivity
analyses.
other cancer types
There were insufficient studies identified to warrant meta-analy-
ses for other cancer types, the findings of which are presented in
Table 3. In head and neck cancer, a positive trend towards
improved RFS and CSS was seen in one study [57], but there was
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no effect on OS. However, the second study identified showed a
potential detriment of metformin use on RFS [58]. In renal cell
carcinoma, two studies were identified, both showing a non-sig-
nificant inverse relationship with metformin use and RFS, and
no significant benefit in OS or CSS. Single studies were identified
showing a significant improvement in OS in lung cancer, RFS
and OS in endometrial cancer and RFS, OS and CSS in gastric
cancer. A small single study in pancreatic cancer did not suggest
any effect of metformin; however, this study had a very small
sample size.
duration and dose
The impact of different exposures to metformin on early-stage
cancer outcomes is examined in some of the identified studies;
however, limited data and differences in the methods used to
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Figure 6. Urothelial cancer outcomes according to metformin use.
Table 3. Cancer outcomes by metformin use for tumour types with limited numbers of studies
Tumour group Study author Sample size Recurrence-free
survival HR (95% CI)
Overall survival
HR (95% CI)
Cancer-specific
survival HR (95% CI)
Head and neck Kwon [57] 1072 0.76 (0.49–1.21) 0.95 (0.59–1.50) 0.79 (0.42–1.50)
Thompson [58] 78 1.26 (0.62–2.56) — —
Renal cell carcinoma Hakimi [59] 784 1.22 (0.66–2.27) — 0.76 (0.21–2.70)
Psutka [60] 200 1.07 (0.61–1.88) 0.74 (0.48–1.15) 0.83 (0.41–1.67)
Pancreas Ambe [61] 44 — 0.54 (0.16–1.68) —
Lung Fortune [62] Not given by stage — 0.85 (0.77–0.93) —
Endometrial Ko [63] 363 0.56 (0.34–0.91) 0.43 (0.24–0..77) —
Gastric Lee, CK [64]a 326 0.86 (0.80–0.94) 0.87 (0.80–0.95) 0.87 (0.78–0.96)
aHR for each 6 months of metformin use.
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investigate exposure preclude any study-group analyses. In col-
orectal cancer, Spillane et al. [38] conducted additional analyses
on dose intensity and found survival benefits for high-intensity
metformin users not using other diabetic therapies (CSS HR
0.44, CI 0.20–0.95; OS HR 0.41, CI 0.24–0.70), but no significant
benefits were identified in other subgroups. In gastric cancer, Lee
et al. [64] found that increased cumulative duration of metfor-
min use improved cancer-specific and all-cause mortality. Single
studies in colorectal [42] and prostate cancer [43] also investi-
gated the impact of different exposures to metformin but found
no significant associations.
discussion
Our analysis suggests that metformin could be a useful adjuvant
agent, particularly in colorectal and prostate cancer. The number
of studies identified for each tumour type is likely to reflect the
incidence and demographics of the disease, particularly the like-
lihood of presentation with early-stage disease and a diagnosis of
DM.
The variation in the adjuvant effects of metformin according
to tumour type could be explained by differences in both patient
characteristics and tumour biology. The effect of metformin on
AMPK signalling has been hypothesised to be a major pathway
through which metformin exerts its anti-cancer effects [10].
AMPK signalling dysregulation is also associated with metabolic
syndrome [65], a cluster of conditions which include raised fast-
ing glucose, dyslipidaemia, high blood pressure and central obe-
sity [66]. Metabolic syndrome is also known to increase the risk
of developing some cancers, particularly colorectal cancer [67],
where it is also associated with poorer recurrence and survival
outcomes [68]. In addition, it is known to develop as a conse-
quence of androgen deprivation therapy in men with prostate
cancer [69]. Metformin may improve OS by reducing the num-
ber of cardiovascular deaths associated with metabolic syn-
drome; however, the improvements in RFS and CSS identified
suggest a direct anti-cancer effect. In prostate cancer, our study
group analysis suggests that the beneficial effects of metformin
use could be limited to those undergoing radical radiotherapy.
The AMPK pathway is known to play a role in regulating cellular
responses to radiotherapy, [70] and studies in xenograft mice
models suggest that metformin can improve tumour oxygena-
tion and therefore radiation response [71].
The limitations of our meta-analysis include the inherent
weaknesses of observational data, particularly potential measure-
ment errors in the exposure to metformin, and variation in the
definition of metformin use, and the risk of time-related biases
[72]. A high degree of variation between the results of studies
was observed for a number of the outcomes investigated in most
of the cancer types. Our sensitivity analyses were designed to
explore possible reasons for this to inform future observational
and clinical trial design; however, only a small number of analy-
ses were possible due to insufficient study numbers. For both
prostate and colorectal cancer, the relative effect size appeared to
increase for studies with follow-up of 3 years or greater, high-
lighting the importance of ensuring adequate duration of follow-
up in future studies. Similarities have been seen in studies of
aspirin, where greater benefits have been seen with longer fol-
low-up [73–75]. A limited number of studies investigated the
relation with frequency, dose and duration of metformin in
early-stage cancer; however, findings are inconsistent and fur-
ther research is required to better understand this relationship.
Previous studies have suggested that a diagnosis of DM has a
negative impact on cancer outcomes [76, 77]; therefore, inclu-
sion of non-DM patients in comparator groups could underesti-
mate the beneficial effect of metformin. Owing to insufficient
study numbers, it was only possible to analyse the effect of the
presence or absence of non-DM patients in the comparator
group for RFS in prostate cancer, where no evidence for an effect
was found.
Other meta-analyses have investigated the effect of metformin
on survival outcomes, across all stages of cancer, in individual
tumour types, the findings of which are presented in supplemen-
tary Table S2, available at Annals of Oncology online. In colorec-
tal cancer, four meta-analyses have examined the effect on OS
[21–24], two of which also investigated colorectal CSS [23, 24].
All meta-analyses identified significant improvements in these
end points, which is consistent with the findings of this study.
For prostate cancer, findings are less consistent. Five meta-analy-
ses have examined the effect of metformin on OS [22, 23, 25–27],
two of which also investigated prostate CSS [25, 26]. Only two
meta-analyses identified a significant benefit in OS [23, 25], with
no benefit identified in prostate CSS. This differs from the find-
ings of this study where significant benefits in OS and prostate
CSS were identified, which could suggest that metformin is better
suited to the adjuvant setting for prostate cancer. In breast can-
cer, four meta-analyses examined OS [21–23, 28], two of which
investigated breast CSS. Two meta-analyses identified a signifi-
cant benefit in OS [21, 23, 28], the other approached significance
(HR 0.81, CI 0..64–1.04) [22] and the two meta-analyses investi-
gating breast CSS also showed significant improvements [23,
28]. This differs from the findings of this study where no signifi-
cant benefit in OS and breast CSS was identified. This could sug-
gest that metformin may be effective in those with established
breast cancer, which is consistent with the findings of breast can-
cer window studies where direct anti-tumour effects have been
identified [13, 14].
Investigation of metformin in the primary prevention setting
presents a number of challenges, where the balance between
adverse effects and benefits is likely to be less favourable and dif-
ficult to detect in a clinical trial because of the low event rate.
While the advanced setting can provide a sufficient event rate,
there is evidence to suggest that metformin requires long-term
use to exert its anti-cancer effect [78], and therefore, patients
with established cancer with more limited prognoses may not be
able to receive metformin long enough for a therapeutic benefit
to emerge. Therefore, the adjuvant setting could be most suitable
for investigating the anti-cancer effects of metformin.
current trial activity
In colorectal cancer, a phase III trial of metformin versus stand-
ard care assessing recurrence and survival in stage III disease
is now in set-up phase in South Korea (NCT02614339). In
prostate cancer, the Metformin Active Surveillance Trial
(NCT01864096), an ongoing randomised phase III trial of met-
formin versus placebo given before primary therapy is assessing
time to progression in men with low-risk prostate cancer. The
Annals of Oncology reviews
Volume 27 | No. 12 | December 2016 doi:10.1093/annonc/mdw410 | 2193
STAMPEDE trial (NCT00268476), a multi-arm multi-stage
randomised, controlled trial investigating a number of agents in
the treatment of hormone-naı¨ve, high-risk, localised and meta-
static prostate cancer, aims to evaluate whether the addition of
metformin improves survival in this group. Recruitment to this
comparison is due to open in autumn 2016. In breast cancer, our
results did not identify any meaningful benefit of metformin use
in the adjuvant setting; however, this could be due to the limited
number of studies identified. Additional supporting data are
available in the primary prevention and treatment setting (across
all stages), where meta-analyses have shown a beneficial effect
[21, 23, 28, 79]. A randomised phase III trial of metformin
versus placebo assessing recurrence and survival in early-stage
breast cancer has recently completed recruitment (MA-32,
NCT01101438) and the results are awaited.
conclusions
The findings of this meta-analysis support the concept of rando-
mised clinical trials using metformin in the adjuvant setting,
with the strongest supporting evidence in colorectal and prostate
cancer, particularly those treated with radical radiotherapy. Such
trials could also further our understanding of the relationships
between cancer outcomes and the dose and duration of metfor-
min. The authors are not aware of any ongoing adjuvant phase
III trials of metformin in prostate cancer, or colorectal cancer in
Western populations. In other tumour types, where there is cur-
rently less evidence, further observational studies are needed to
advise suitability for investigation in any future randomised,
controlled trials.
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